Navigation Links
Off-Label Use of Clotting Drug Soars, Report Finds
Date:4/18/2011

MONDAY, April 18 (HealthDay News) -- Hospitals are using a pricey blood-clotting drug in treating people who do not have hemophilia, a rare disorder in which blood does not clot normally -- even though its use in such patients is potentially risky, according to new research.

Stanford University researchers found that use of the drug, known as recombinant factor 7a, grew by 140 times from use in 125 cases in 2000 to 17,813 in 2008, with off-label uses accounting for most of the increase.

The $10,000-a-dose drug was used in people with hemophilia just 4 percent of the time, according to U.S. hospital statistics from 2000 to 2008. The rest of the time, it was used during heart surgery and to treat medical problems such as trauma and bleeding in the brain. The researchers content that such use puts patients at risk for heart attack and stroke because the drug can boost the risk of blood clots.

"The stakes are high with this one," Dr. Veronica Yank, an instructor in medicine at Stanford and the first author of one of two new studies on the drug, said in a university news release. "Because it's such a powerful clotting agent, it has the potential when used off-label to damage the lives of patients without providing any real benefit."

Yank and her colleagues said that physicians should be more cautious with the drug until there's more research into whether it's appropriate to use in certain cases.

The studies, published April 19 in Annals of Internal Medicine, are accompanied by a commentary from Harvard Medical School researchers, which says the research provides "compelling data about the runaway use, uselessness and risk for this expensive treatment."

The studies were funded by the U.S. Agency for Healthcare Quality and Research after previous research raised concerns that RF7a increased the risk for blood clots. The agency asked for an assessment of five off-label uses of RF7a: heart surgery, intracranial hemorrhage, body and brain trauma, liver transplantation and prostate surgery.

More information

The U.S. National Heart, Lung and Blood Institute has more on hemophilia.

-- Randy Dotinga

SOURCE: Stanford University School of Medicine, news release, April 18, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Hemophilia Drug Used Off-Label Raises Clot Risk
2. Anti-clotting agent does not improve outcomes of patients with severe pneumonia
3. New Anti-Clotting Drug May Work Better After Hip Replacement
4. Extended use of anti-clotting drug helps some bedridden patients
5. Tests to Measure Safety of Anti-Clotting Drugs of Limited Value
6. TBI Therapy and Nutrition: IOM report releases April 20
7. Boston University researchers find most substance-dependent individuals report poor oral health
8. Making temporary changes to brain could speed up learning, study reports
9. Aerobic Exercise May Curb Non-Alcoholic Fatty Liver Disease: Report
10. Brisk Walk Can Boost Blood Flow to the Brain: Report
11. U.S. Reports Drop in AIDS-Related Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Off-Label Use of  Clotting Drug Soars, Report Finds
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... agency serving communities in the greater Dallas, Miami, and Raleigh regions, is organizing ... fighting to overcome a rare and deadly chromosome abnormality. , After struggling since ...
(Date:10/13/2017)... Milwaukee, WI (PRWEB) , ... October 13, 2017 , ... ... movement in medicine known as “patient engagement.” The patient is doing more than filling ... research partners. , “There is an increasing emphasis in health care and research ...
(Date:10/13/2017)... ... ... The American Board of Family Medicine's (ABFM) Board of Directors has selected Warren ... James C. Puffer upon his retirement. Dr. Newton will serve in the position of ... end of 2018. Upon assuming the role of President and CEO on January 1, ...
(Date:10/13/2017)... Nevada (PRWEB) , ... October 13, 2017 , ... ... Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil ... required and providing a CBD form that can be easily incorporated into liquid products, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of the Law ... organization of elder law and special needs planning attorneys. “Membership in ElderCounsel helps our ... a forum to network with elder law attorneys nationwide,” said Somekh. , ...
Breaking Medicine News(10 mins):
(Date:9/18/2017)... , Sept. 18, 2017 EpiVax, ... of bioinformatics and immune engineering, today announced ... influenza A (H7N9) vaccine. ... to seasonal influenza and presents a challenge ... prior exposure to be effective. Using state-of-the-art ...
(Date:9/12/2017)... NEW YORK , Sept. 12, 2017   EcoVadis , ... supply chains, has published the first annual edition of its Global CSR ... than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed ... ... & Performance Index ...
(Date:9/12/2017)... 2017  ValGenesis Inc., the global leader in ... to announce the appointment of Dr. Ajaz ... of Directors and Chairman of Advisory Board beginning ... companies to manage their entire validation lifecycle process ... this process. Furthermore, ValGenesis VLMS enables rigorous compliance, ...
Breaking Medicine Technology: